Truist Financial Lowers Astrana Health (NASDAQ:ASTH) Price Target to $46.00

Astrana Health (NASDAQ:ASTH) had its price objective reduced by equities research analysts at Truist Financial from $50.00 to $46.00 in a research report issued on Tuesday,Benzinga reports. The firm presently has a “buy” rating on the stock. Truist Financial’s target price points to a potential upside of 45.99% from the company’s current price.

Several other research analysts have also issued reports on ASTH. Stifel Nicolaus dropped their price target on shares of Astrana Health from $70.00 to $56.00 and set a “buy” rating for the company in a research report on Thursday, February 20th. Macquarie raised Astrana Health to a “hold” rating in a report on Monday, December 16th. Bank of America cut their price target on shares of Astrana Health from $55.00 to $49.00 and set a “buy” rating for the company in a report on Tuesday, March 4th. Finally, Robert W. Baird reduced their target price on Astrana Health from $86.00 to $50.00 and set an “outperform” rating on the stock in a report on Monday, March 3rd. Two research analysts have rated the stock with a hold rating, six have given a buy rating and one has assigned a strong buy rating to the company. Based on data from MarketBeat, Astrana Health currently has an average rating of “Moderate Buy” and a consensus target price of $56.17.

Astrana Health Price Performance

Shares of ASTH stock opened at $31.51 on Tuesday. Astrana Health has a 12 month low of $23.12 and a 12 month high of $63.20. The company has a market capitalization of $1.77 billion, a P/E ratio of 24.24, a P/E/G ratio of 1.37 and a beta of 1.30. The stock has a 50 day moving average of $33.96 and a two-hundred day moving average of $42.76. The company has a current ratio of 1.91, a quick ratio of 1.91 and a debt-to-equity ratio of 0.60.

Astrana Health (NASDAQ:ASTH) last issued its earnings results on Thursday, February 27th. The company reported ($0.15) EPS for the quarter, missing the consensus estimate of $0.22 by ($0.37). Astrana Health had a return on equity of 9.37% and a net margin of 3.63%. The firm had revenue of $665.21 million during the quarter, compared to the consensus estimate of $617.24 million. As a group, equities analysts expect that Astrana Health will post 1.15 EPS for the current year.

Institutional Trading of Astrana Health

A number of hedge funds and other institutional investors have recently modified their holdings of ASTH. Victory Capital Management Inc. bought a new stake in Astrana Health during the 3rd quarter worth about $2,596,000. KBC Group NV bought a new stake in shares of Astrana Health during the third quarter worth approximately $70,000. Natixis Advisors LLC acquired a new position in Astrana Health in the third quarter valued at approximately $1,621,000. Mutual of America Capital Management LLC bought a new position in Astrana Health in the third quarter valued at approximately $362,000. Finally, Thrivent Financial for Lutherans acquired a new stake in Astrana Health during the 3rd quarter worth $1,890,000. Institutional investors and hedge funds own 52.77% of the company’s stock.

Astrana Health Company Profile

Astrana Health, Inc, Inc, a physician-centric technology-powered healthcare management company, provides medical care services in the United States. It operates through three segments: Care Partners, Care Delivery, and Care Enablement. The company is leveraging its proprietary population health management and healthcare delivery platform, operates an integrated, value-based healthcare model which empowers the providers in its network to deliver care to its patients.